Synthetic lethality is a therapeutic strategy frequently implemented using PARP inhibitors, as evidenced by their role in clinical trials [1] and research into overcoming resistance [2]. Furthermore, synthetic lethality is actively pursued in combination with PARP inhibition to treat specific cancers like pancreatic cancer {fact:3, fact:4}.